A comparison of the effect of ramipril, felodipine and placebo on glomerular filtration rate, albuminuria, blood pressure and vasoactive hormones in chronic glomerulonephritis: A randomized, prospective, double- blind, placebo-controlled study over two years

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 57, Issue 8, 1997, Pages 673-681

  Pedersen, E B ^a   Bech, J N ^a   Nielsen, C B ^a   Kornerup, H J ^a   Hansen, H E ^a   Spencer, E S ^a   Solling J ^a   Jensen, K T ^a  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Albuminuria; Aldosterone; Angiotensin II; Atrial natriuretic peptide; Brain natriuretic peptide; Endothelin; Felodipine; Glomerular filtration rate; Glomerulonephritis; Hypertension; Prostaglandin; Ramipril; Vasopressin

Indexed keywords

CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FELODIPINE; RAMIPRIL;

ADULT; AGED; ARTICLE; CHRONIC GLOMERULONEPHRITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL;

GLOMERULUS;

EID: 0031435523     PISSN: 00365513     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365519709105228     Document Type: Article

References (23)

1. Hannedouche T, Landais P, Goldfarh B, El Esper N, Fournier A, Godin M, Durand D, Chenard J, Mignon F, Suc J-M, Grünfeld J-P. Randomised controlled trial of enalapril and β-blockers in non-diabetic chronic renal failure. Br Med J 1994; 309: 833-77.
2. Maschio G, Alberti D, Janin G, Locatelli F, Mann J, Motolese M, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939-45.
3. Brunner FP, Theil G, Hermle M, et al. Long-term enalapril and verapamil in rats with reduced renal mass. Kidney Int 1989; 36: 969-77.
4. Dworkin LD, Benstein JA, Parker M, et al. Calcium antagonists and converting enzyme inhibitors reduce renal injury by different mechanisms. Kidney Int 1993; 43: 808-14.
5. Tolins JP, Raij L. Comparison of converting enzyme inhibitor and calcium channel blocker in hypertensive glomerular injury. Hypertension 1990; 16: 452-61.
6. Zucchelli P, Zuccala A, Borghi M, Fusaroli M, Sasdelli M, Stallone C, et al. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 1992; 42: 452-8.
7. Brøchner-Mortensen J, Rødbro P. Selection of routine method for determination of glomerular filtration rate in adult patients. Scand J Clin Lab Invest 1976; 36: 35-43.
8. Pedersen EB, Eiskjær H, Madsen B, Danielsen H, Egeblad M, Nielsen CB. Effect of captopril on renal extraction of renin, angiotensin II, atrial natriuretic peptide and vasopressin, and renal vein renin ratio in patients with arterial hypertension and unilateral renal artery disease. Nephol Dial Transplant 1993; 8: 1064-70.
9. Jensen KT, Pedersen EB. A new radioimmunoassay for brain natriuretic peptide in plasma and reference values in different diseases. Scand J Clin Lab Invest 1997. In press.
10. Brenner BM. Nephron adaptation to renal injury or ablation. Am J Physiol 1985; 249: F324-F337.
11. Jackson B, Johnston CI. The contribution of systemic hypertension to progression of chronic renal failure in the rat remnant kidney: effect of treatment with an angiotensin converting enzyme inhibitor or a calcium inhibitor. J Hypertens 1988; 6: 495-501.
12. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension. J Clin Invest 1986; 77: 1993-2000.
13. Loutzenhiser RD, Epstein M. Calcium antagonists and renal hemodynamics. Am J Physiol 1985; 249: F619-F629.
14. Romero C, Raij L, Granger JP, et al. Multiple effects of calcium entry blockers on renal function in hypertension. Hypertension 1987; 10: 140-51.
15. Bergström J, Alvestrand A, Bucht A, Gutierrez A. Progression of chronic renal failure in man is retarded with more frequent clinical follow-ups and better blood pressure control. Clin Nephrol 1986; 25: 1-6.
16. Brazy PC, Fitzwilliam JF. Progressive renal disease: role of race and antihypertensive medications. Kidney Int 1990: 37: 1113-9.
17. Mann JFE, Reisch C, Ritz E. Use of angiotensin converting enzyme inhibitors for preservation of kidney function. Nephron 1990; 55 Suppl 1: 38-42.
18. Rodicio JL, Alcazar JM, Ruilope JL. Influence of converting enzyme inhibition on glomerular filtration and proteinuria. Kidney Int 1990; 38: 590-4.
19. Rekola S, Bergstrand A, Bucht H. Deterioration rate in hypertensive IgA nephropathy: comparison of an converting enzyme inhibitor and betablocking agents. Nephron 1991; 59: 57-60.
20. Bianchi S, Bigazzi R, Baldari G, Campese VM. Long-term effects of enalapril and nicardipine on urinary albumin excretion in patients with chronic renal insufficiency: a 1-y follow-up. Am J Nephrol 1991; 11: 131-7.
21. Kampner AL, Strangaard S, Leyssac P. Effect of enalapril on the progression of chronic renal failure. Am J Hypertens 1992; 5: 423-30.
22. Weidmann P, Boehlen LM, de Courten M. Effects of different antihypertensive drugs on human diabetic proteinuria. Nephrol Dial Transplant 1993; 8: 582-4.
23. Brøckner-Mortensen J. Current status on assessment and measurement of glomerular filtration rate. Clin Physiol 1985; 5: 1-17.